Medical management of primary pulmonary hypertension.
Primary pulmonary hypertension (PPH) is a poorly understood, progressive disease that is characterized by elevation of pulmonary artery pressure and vascular resistance, leading to right ventricular failure and death within 2-3 yrs after diagnosis. Based upon the concept that vasoconstriction and thrombotic occlusion of resistance vessels precipitate this process, vasodilator therapy and anticoagulation have become the main strategies for improving survival in these patients. Whereas, a few years ago, medical therapy of primary pulmonary hypertension was perceived as a bridging therapy to lung or heart lung transplantation, modes of therapy are being clinically tested at this time to offer an alternative to the surgical treatment of this disease. However, no selective pulmonary vasodilator is yet available. Therefore, and because of the potential hazards of vasodilator treatment, standardized haemodynamic testing is performed prior to initiation of vasodilator treatment. In this update, the currently available compounds both for haemodynamic testing and chronic therapy, their mode of action, method of administration and efficacy are reviewed.
Kneussl
M P
MP
Dept of Internal Medicine IV (Pulmonary Medicine), Pulmonary Hypertension Clinic of the Vienna General Hospital, University of Vienna, Austria.
Lang
I M
IM
Brenot
F P
FP
D000925:Anticoagulants / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage; D011464:Epoprostenol / Q000008:administration & dosage; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000925:Anticoagulants; D000959:Antihypertensive Agents; D014665:Vasodilator Agents; D011464:Epoprostenol